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Abstract
Background: Chromatin-modifying reagents that alter histone associating proteins, DNA conformation or its sequence
are well established strategies for studying chromatin structure in interphase (G1, S, G2). Little is known about how these
compounds act during metaphase. We assessed the effects of these reagents at genomic loci that show reproducible,
non-random differences in accessibility to chromatin that distinguish homologous targets by single copy DNA probe
fluorescence in situ hybridization (scFISH). By super-resolution 3-D structured illumination microscopy (3D-SIM) and other
criteria, the differences correspond to ‘differential accessibility’ (DA) to these chromosomal regions. At these chromosomal
loci, DA of the same homologous chromosome is stable and epigenetic hallmarks of less accessible interphase chromatin
are present.
Results: To understand the basis for DA, we investigate the impact of epigenetic modifiers on these allelic differences in
chromatin accessibility between metaphase homologs in lymphoblastoid cell lines. Allelic differences in metaphase
chromosome accessibility represent a stable chromatin mark on mitotic metaphase chromosomes. Inhibition of the
topoisomerase IIα-DNA cleavage complex reversed DA. Inter-homolog probe fluorescence intensity ratios between
chromosomes treated with ICRF-193 were significantly lower than untreated controls. 3D-SIM demonstrated that
differences in hybridized probe volume and depth between allelic targets were equalized by this treatment. By contrast,
DA was impervious to chromosome decondensation treatments targeting histone modifying enzymes, cytosine
methylation, as well as in cells with regulatory defects in chromatid cohesion. These data altogether suggest that DA is a
reflection of allelic differences in metaphase chromosome compaction, dictated by the localized catenation state of the
chromosome, rather than by other epigenetic marks.
Conclusions: Inhibition of the topoisomerase IIα-DNA cleavage complex mitigated DA by decreasing DNA superhelicity
and axial metaphase chromosome condensation. This has potential implications for the mechanism of preservation of
cellular phenotypes that enables the same chromatin structure to be correctly reestablished in progeny cells of the same
tissue or individual.
Keywords: Chromosome decondensation, Metaphase chromosome structure, Super-resolution microscopy, DNA
Topoisomerases Type II, Fluorescence In Situ Hybridization, Epigenetics
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Background
Large-scale chromatin reorganization from interphase to
metaphase is driven by mitotic-specific condensation
factors [1, 2]. Broadly speaking, this is thought to include
histone proteins undergoing post translational modifications and interaction of histone tails with neighboring
nucleosomes [1]. This is complemented with a network
of non-histone proteins such as DNA methyltransferases
involved in chromatin remodeling [3]. At later stages of
the cell cycle, solenoidal supercoiling by topoisomerase
concomitant with structural maintenance of chromosomal (SMC) proteins [4] further influences the condensation process.
Previous studies have used chromatin modifying reagents to study chromosome biology and investigate
the large scale folding of the chromatin fiber. This has
been performed, for instance, using chemical inhibitors
which disrupt canonical chromatin-associating proteins
[5–9] or enzymes which map chromatin accessibility in
the human genome [10]. Our interest in chromatin accessibility arose out of an observation that short, locusspecific, single copy DNA probes detect differences in
DNA compaction between homologs at ~10 % of allelic
loci on mitotic metaphase chromosomes [11–13]. This
is referred to as differential accessibility (or DA) to specific, condensed chromosomal targets. In human
lymphocyte and lymphoblastoid cells, DA was nonrandom, heritable, and not unique to imprinted regions
[13]. This led to the suggestion that DA represents an
intergenerational mechanism of storing epigenetic information in mitotic metaphase chromosomes between
parent and daughter cells [13].
The underlying basis for DA is not known. Here, we
assess the contributions of different epigenetic factors
towards these allelic differences in chromatin accessibility during metaphase. Cells are treated with chromatinmodifying reagents that are known to alter chromosome
condensation, with the objective of providing insight
into the basis of DA during mitotic metaphase.

Results
Effects of chromatin-modifying reagents on metaphase
chromatin

Chromosome condensation was altered in two lymphoblastoid cell lines (GM06326, GM10958 obtained from
NIGMS Cell Repository [Camden]) by separately
treating them with several reagents, known to modify
chromatin. Treatments were directed at essential DNA
modifications, proteins altering DNA structure, and
histone proteins with established roles in chromatin
compaction and remodeling [1, 2, 8]. We assessed
chromosome decatenation by inhibiting topoisomerase
IIα with ICRF-193, histone dephosphorylation with
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okadaic acid (OA), histone deacetylation with trichostatin A (TSA), histone H3K27me3 demethylation with
UNC1999, and DNA hypomethylation by incorporation of 5-azacytidine (5-AZC). We also analyzed metaphase chromosomes from cell lines of patients with
cohesin mutations (Additional file 1: Table S1, GM20000
and GM20466).
Chromatin-modifying inhibitor concentrations were
optimized in the cell lines to establish cytogenetic or immunofluorescence phenotypes in which the inhibitors’
effects were clearly detectable microscopically, without
significantly compromising mitotic indices or chromosome identification. Compared to untreated controls
(Fig. 1a), chromosome decatenation was decreased with
0.10–0.50 μM ICRF-193, which resulted in longer,
entangled metaphase chromosomes (Fig. 1b-d, Additional
file 2: Figure S1). Longer chromosomes (based on the
International System for Human Cytogenetic Nomenclature, ISCN 2013 [14]) were apparent with increasing
concentrations of ICRF-193. This was obvious at 0.25 and
0.5 μM concentrations, where there was a statistically
significant shift in the 550 to < 700 band resolution
category and the ≥ 700 band resolution category (F =
9.86, p = 0.0015). There was no significant difference in
the 300 to < 400 and the 400 to < 550 band level categories (F = 1.93, p = 0.180) among untreated and
ICRF-193 treated metaphases.
Incubation with 0.25 μM and 0.50 μM OA caused premature chromosome condensation (PCC) (Fig. 1e-f), as
previously documented [5]. Inhibition of histone deacetylation and K27 trimethylation by TSA (at 0.40 μM and
15.0 μM) and UNC1999 (at 5.0 μM and 15.0 μM), respectively, produced metaphase chromosomes similar in
morphology to untreated control metaphase chromosomes. For TSA (0.40 μM and 15.0 μM), a decrease in diploid mitotic cells (~1 % vs 5-6 % for untreated cells) and
detection of occasional polyploid cells were also observed.
For UNC1999 treatment, effects were confirmed by demonstrating substantially lower H3K27me3 immunofluorescence of interphase nuclei (Additional file 3: Figure S2).
At the highest dose of UNC1999 [45 μM], absence of
metaphase cells precluded further analysis. Incubation
with 17.5 μM and 35.0 μM of 5-AZC showed decondensed heterochromatic regions (Fig. 1g), as previously reported [8]. At lower concentrations of 5-AZC (i.e. 3.5 μM
and 7.0 μM), decondensation was not evident. As expected [15], immortalized cells from an individual with SC
phocomelia showed absence of primary constriction
(Fig. 1h) and/or heterochromatic repulsion (Fig. 1i) in
chromosomes due to a cohesin mutation in ESCO2
(Additional file 1: Table S1). Chromosomes of an individual with Cornelia de Lange Syndrome and a mutation
in NIPBL, another cohesin gene, exhibited apparently normal morphology.
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Fig. 1 Decondensation treatments with visible effects on metaphase chromosome morphology. a Normal metaphase cell with no treatment. b–d
ICRF-193 treated cells at increasing drug concentrations (0.10, 0.25 and 0.50 μM; left to right) show increasingly elongated chromosomes. OA treated
cells with (e) early condensation at S and (f) late S phase of cell cycle. g 5-AZC treated metaphase chromosomes showing heterochromatin regions
that did not condense (arrows). h Cell from individual with SC phocomelia (mutation in ESCO2 c.604C > T, c.752delA, exon 3) showing premature sister
chromatid separation primarily at heterochromatic regions near centromeres and (i) heterochromatic repulsion (arrows) in most pericentromic regions
resulting in a railroad track appearance to the chromosomes. Metaphase chromosomes from Cornelia de Lange individual (NIPBL c.5721del5, exon 31)
appeared similar to untreated normal cells (panel a)

Targeting topoisomerase IIα eliminates inter-homolog
chromatin accessibility differences in metaphase at
distinct loci with DA

In prior studies where we documented DA at ~ 10 % of the
305 genomic loci [11–13], ≥ 66 % of metaphase cells (twoproportion Z-test, p < 0.05) consistently exhibited nonrandom differences in DNA probe fluorescence intensity
between homologous regions [13]. A set of single copy (sc)
DNA probes for fluorescence in situ hybridization (scFISH),

from imprinted and non-imprinted loci (RGS7; 2.09 kb,
CACNA1B; 2.23 kb, HERC2; 1.82 kb, SNRPN; 2.08 kb,
ADORA2B; 1.78 kb, PMP22:IVS3; 2.32 kb, ACR; 3.5 kb, see
Additional file 1: Table S1 for genomic coordinates), were
hybridized to metaphase chromosomes and scored for DA
according to these criteria [13].
We examined the effects of modifiers of chromatin accessibility that alter DNA compaction (topoisomerase IIα)
on DA (Fig. 2a). Inhibition of chromosome decatenation
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Fig. 2 Representative example of differential accessibility (DA) and its reduction with topoisomerase IIα inhibitor ICRF-193. a Metaphase cell showing
chromosome 1 homologs hybridized with single copy DNA FISH probe from within RGS7 (2.09 kb). Relative to its homolog, * marks the chromosome
with the weaker probe hybridization signal; indicating DA. Inset shows metaphase cell with homologs of interest (boxed). b-c Ladder plots compare
effect of topoisomerase IIα inhibitor, ICRF-193, on DA at various concentrations and genomic loci in two lymphoblastoid cell lines. Colored lines
connecting two points, pre and post-treatment (x axis), represent different genomic targets as indicated in the key. Frequency of DA to homologous
regions is expressed as a percentage (y axis). Greater than two-thirds (dotted line) of the cells analyzed (n = 20–100 cells, μ = 43 cells/per target) in
pre-treatment control showed DA. b In cell line GM06326, with the exception of HERC2, DA was significantly reduced post-treatment
(z-score < −2.0, p < 0.05, two-proportion z test) at distinct genomic targets. c These findings were reproduced in a second cell line,
GM10958, however in this case, reduction in DA was marginally significant at PMP22:IVS3 and ACR (indicated by *)
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with the topoisomerase IIα inhibitor, ICRF-193, eliminated
DA at multiple single copy loci, equalizing probe intensities
on both homologs. This loss of DA was noted at multiple
genomic targets in ICRF-193 treated cells (Fig. 2b-c), including RGS7, CACNA1B, ADORA2B, PMP22:IVS3, and
ACR. It was related to a decrease in the amount of decatenation, resulting in reduced chromosome supercoiling. The
effects of ICRF-193 on DA varied for certain genomic targets (e.g. PMP22:IVS3, ACR), between the cell lines
(Fig. 2b-c). HERC2 was the only exception of a locus that
maintained differences in accessibility (DA) across a range
of ICRF-193 concentrations (Fig. 2b-c, Additional file 1:
Table S1). We suggest that the genomic context of this gene
may explain the lack of response (see Discussion).
Quantification of chromatin accessibility following
topoisomerase IIα inhibition

We quantified differences in probe hybridization between
homologous loci using gradient vector flow (GVF) image
analysis after ICRF-193 treatment, and compared results to
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untreated cells [13, 16] (Fig. 3, Additional file 4: Figure S3).
Intensity differences in mean normalized probe fluorescence after ICRF-193 treatment were reduced by 2-fold
(Δμ = 0.352) relative to untreated control cells (Δμ = 0.725)
for RGS7, CACNA1B, ADORA2B, PMP22:IVS3, and ACR
(Fig. 3, Additional file 4: Figure S3), indicating that the drug
equalizes accessibility of the probe to both homologous targets. In contrast, the intensities of a probe detecting DA
within HERC2 were similar in treated (Δμ = 0.662) and
untreated cells (Δμ = 0.713) (Fig. 3c, Additional file 4:
Figure S3C).
Super-resolution, 3-dimensional structured illumination microscopy (3D-SIM) provided direct evidence of
the effects of ICRF-193 on equalization of chromosome
target accessibility. 3D-SIM increases the spatial resolution with which metaphase chromatin accessibility
can be visualized and quantified. Larger volumes and
greater depths of probe hybridization are consistent
with decreased condensation and lower DNA superhelicity. Quantification of the volumes occupied by the

Fig. 3 Quantification of inter-homolog fluorescence intensities following chromosome decondensation with ICRF-193. a-f FISH with single copy
probes targeting six distinct genomic regions within chromosomes 1q43 (RGS7), 9q34.3 (CACNA1B), 15q13.1 (HERC2), 17p12 (ADORA2B,
PMP22:IVS3), and 22q13.33 (ACR) are indicated. For untreated chromosomes (left column, panels a-f, respectively), probe signal is bright on one
homolog and appears dim or not visible on corresponding target (*). For chromosomes treated with ICRF-193, (middle column, panels a-f,
respectively) probe signal is bright on both homologs. Probes detecting DA exhibited larger differences in inter-homolog DNA probe fluorescence
(red box plots in right column: median intensity ratios: from 0.53 to 1, n = 125 cells). ICRF-193-treated chromosomes exhibited smaller differences
in DNA probe fluorescence (black box plots in right column: median intensity ratios from 0.08-0.27, n = 121 cells) (p < 0.05; two tail t-test),
suggesting that both chromosomal homologs were equally accessible, except at the HERC2 locus, where DA was not completely reversed. In
instances where the median is coincident with the upper quartile, it is emphasized by a thick line to show distinction with median in corresponding
category. The notation ‘der 17’ refers to a derivative chromosome 17 homolog resulting from a translocation between chromosome Y and 17
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hybridized probe showed large differences in the distributions of probe depth between homologs in untreated
cells with DA (for example, PMP22:IVS3; Fig. 4a). By
contrast, Fig. 4b shows the effects of ICRF-193 treatment with the same probe, notably that both chromosomes are hybridized to similar depths and occupy
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equivalent volumes, consistent with abrogation of DA.
Overall, probe volumes and depths were consistently
different between untreated and treated categories
(Fig. 4c). The differences in probe hybridization volume
are also visualized with 3D-anaglyph displays of untreated
(Additional file 5: Movie S1) and ICRF-193-treated

Fig. 4 Visualization of internal chromosome accessibility with super resolution 3D-SIM. a Untreated metaphase cell showing DA between chromosome
17 homologs (left panel, circled) hybridized with single copy FISH probe within PMP22:IVS3 (2.32 kb). Probe depth spans 1.30 μm or 10 of 17
(middle panel, red boxes*) and 0.65 μm or 5 of 17 (right panel, red boxes*) optical sections within accessible and less accessible homologs,
respectively. b Decondensed metaphase chromosomes (left panel, boxed) hybridized with same PMP22:IVS3 (2.32 kb) single copy probe
exhibit equal accessibility to both homologs. Probe depth (10 of 17 and 11 of 17 sections) for each homolog spans 1.30 μm (middle panel)
and 1.43 μm (right panel), respectively. Same cell line (GM06326) is used in (a) and (b). Crosshairs are over maximal fluorescence. Der 17 refers
to derivative chromosome 17. This was used as a cytogenetic marker to distinguish parental homologs. c Scatterplot of individual cells showing
differences in hybridized probe volume and depth for untreated and treated cells. Normalized mean differences in hybridized probe volume
(Δμ = 0.730 μm3, circles) and depth (Δμ = 0.651 μm, squares) for different untreated cells (n = 10 cells) for genomic target (PMP22:IVS3) with DA. These
were significantly greater (volume: p = 0.003, depth: p = 0.013; two-tailed t test) compared to the same genomic target post-treatment
(indicated with squares) in which both alleles were accessible (volume: Δμ = 0.237 μm3, depth: Δμ = 0.238 μm, n = 9 cells). Single cell outliers (ymax
or xmax) with ICRF-193 treatment did not affect p-value cut off (α = 0.05). Normalized probe volume and depth were not strongly correlated
pre- (r = 0.559) and post-treatment (r = 0.164). *Left red box is position zero for all panels in (a) and (b)
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(Additional file 6: Movie S2) chromosome homologs
from the same metaphase cells.
Inhibitors of histone modifications, cytosine methylation,
and mutations in cohesin, a non-histone protein, do not
alter DA

We also examined the effects of histone modifications that
typically influence interphase chromatin accessibility on
DA in metaphase. Differences in probe hybridization intensity were unperturbed by treatment with either OA or TSA
(Fig. 5a-b, Additional file 1: Table S1). Besides prematurely
condensed diploid cells, OA also produced a rare population of prematurely condensed tetraploid-like cells [due to
unscheduled DNA replication [17], in which the extra pair
of homologs did not hybridize using probes from within
distinct genomic targets (ADORA2B with DA or
PMP22:IVS-Ex5 no DA, Additional file 7: Figure S4). This
suggests that these cells have to complete mitosis in order
to re-establish their respective allelic accessibility patterns.
Inhibition of H3K27me3, a characteristic of transcriptionally repressed chromatin [7] and reported to be distributed
across metaphase chromosomes [18], by UNC1999 also
had no effect on DA (Fig. 5c, Additional file 1: Table S1).
For all probes and both cell lines, at least 66 % of metaphase cells (n = 20–100 cells, μ = 43 cells/per genomic target) retained differences in fluorescence intensities for each
probe (Fig. 5a-c, Additional file 1: Table S1). Also, DA was
not altered by loss of DNA methylation (Fig. 5d, Additional
file 1: Table S1) or mutations in two different cohesin genes
(Fig. 5e, Additional file 1: Table S1).

Discussion
In this study, we investigated epigenetic modifications responsible for allelic differences in chromatin accessibility
reported between homologous mitotic metaphase chromosomes [13]. Our results demonstrate that accessibility
differences between allelic loci on metaphase chromatin
can be equalized by inhibition of topoisomerase IIα, which
controls levels of DNA superhelicity during condensation
[19], and do not reflect underlying histone modifications [20], regional decompaction by cohesin mutations
[21, 22], or effects of deoxycytosine methylation [8].
ICRF-193 attenuates variation in epifluorescent probe
signal intensities from specific loci that exhibited DA
(Fig. 2, Fig. 3 and Additional file 4: Figure S3) and this
attenuation was further confirmed by quantifying hybridized probe depth and volume using super-resolution
3D-SIM (Fig. 4). ICRF-193 is a bisdioxopiperazine compound that disrupts the catalytic activity of ATP-bound
DNA topoisomerase IIα, rendering the enzyme inactive
and preventing DNA decatenation [19, 23]. ICRF-193
was selected as there was evidence for its ability to affect
chromatin condensation in mitotic metaphase without
causing cell death [9]. We recognize, however, that the
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catalytic activity of topoisomerase IIα is required at multiple steps of decatenation (including DNA binding,
cleavage or strand passage); however, it is not certain
where in the topoisomerase reaction cycle [19, 23], DA
is attenuated.
ICRF-193 has also been used to produce decondensed
metaphase chromosomes for high resolution chromosome
analysis [9]. The feasibility of this approach to reduce condensation of mitotic chromosomes in order to increase
chromosome length, DNA accessibility, or alter gene expression has previously been demonstrated [24–26]. Different inhibitors of topoisomerase IIα [19] can prevent
DNA binding by topoisomerase IIα, compete with ATP
(simocyclinone d8), block ATPase activity (novo- and cholorobiocins) or are irreversible, effectively poisoning the
enzyme (etoposides) [19]. Assays for DA that alter chromatin condensation should avoid those with high cytotoxic and genotoxic effects, such as doxorubicin.
Attenuation of DA required a specific and sustained
effect on metaphase chromosome decompaction, without loss of chromosome integrity. Inhibiting the catalytic
activity of topoisomerase IIα changes the overall morphology of mitotic chromosomes (Fig. 1b–d, Additional file 2:
Figure S1) by altering levels of axial condensation, leading
to extended, catenated metaphase chromosomes [9]. ICRF193 specifically hinders compaction of 300-nm chromatin
fibers to form into chromatids with prometaphase-level
compaction [27]. Since ICRF-193 targets the early stages
(prophase, pre-metaphase) of mitotic chromosome condensation [27], DA seems most likely to become established in
early metaphase. Inhibiting or disrupting metaphase
chromosome compaction and reversal of DA likely depends
on the stage of chromosome condensation at which the inhibitor acts. Our findings are consistent with the possibility
that by changing DNA topology, less accessible DNA targets on one homolog become more accessible. Distinct
levels of DNA catenation of each homolog could be established, for example, through differences in the local concentration of topoisomerase IIα bound to metaphase
chromosomes [24], structural differences between homologs that impact substrate accessibility at the target
chromosome loci or a combination of both.
Topoisomerase IIα is rapidly degraded as the cell enters G1. This is followed by a rise in its expression at
G2/M, which is greatest among proliferating cells [28].
An increase in log phase growth or expression of topoisomerase IIα lowers sensitivity to topoisomerase inhibitors [29]. Thus, the degree to which endogenous
topoisomerase IIα is inhibited by ICRF-193 in culture is
likely to vary. This is relevant since loss of DA, while
evident in both cell lines (e.g. GM06326, GM10958), did
not occur to the same degree at the PMP22:IVS3 and
ACR loci (Fig. 2b-c). The genomic target within HERC2
notably showed similar percentages of DA in ICRF-193
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Fig. 5 (See legend on next page.)
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(See figure on previous page.)
Fig. 5 Pre- and post-treatment effects of chromatin-modifying reagents and cells with cohesin mutations on DA. a–e. Ladder plots compare
fraction of DA (i.e. expressed as a percentage along y axis) with (+) and without (−) chromatin-modifying reagents at various concentrations
(x axis). Fraction of DA is illustrated with solid and dashed lines for GM06326 and GM10958 cells, respectively. Each line color corresponds to a
different probe (indicated in key; RGS7, CACNA1B, ADORA2B, PMP22:IVS3, SNRPN, HERC2) or control probes exhibiting equal accessibility (C9orf66,
PMP22:IVS4-Ex5). a-c In all cases, greater than two-thirds of the cells analyzed (n = 20–100, μ = 43 cells/per target) maintained DA pre- and
post- reagent treatment in both cell lines at all concentrations tested. Black dotted line indicates threshold for DA. This suggests allelic chromatin
accessibility differences were not reversed with chromatin-modifying reagents targeting histone proteins. This was also true for chromatin-modifying
reagents that prevent (panel d) cytosine methylation or cohesin mutations (panel e) in cells from individuals with Cornelia de Lange Syndrome
(CdLS) and SC-phocomelia Syndrome. Probes that do not detect DA, C9orf66 and PMP22:IVS4-Ex5, were hybridized to cell lines with cohesin
mutations, as controls. Outlier in panel D (PMP22:IVS3) refers to ~ 60 % of the cells (n = 41 cells total) with DA in cell line GM06326 following
5-AZC [17.5 μM]

treated and untreated cells (Fig. 2b-c). One possible explanation for this is the presence of extremely long palindromes (~210 kb), adjacent to and including HERC2
segmental duplications [30], that might result in structural configurations that are simply recalcitrant to
hybridization [31] or experimentally-induced chromosome decompaction.
Changes in chromatin accessibility have been associated with post-translational modifications to histones
[20]. While we did not observe an effect from histone
modifying enzymes, DNA modifications (DNMT1) or
cohesin mutations on reversing DA (Fig. 5), it remains
possible they could contribute to the observed allelic
structural differences. In particular, histone modifications tend to be dynamic, are active at earlier points in
the cell cycle, and often have antagonistic [20] effects on
chromatin structure [6, 17, 20], which could mask their
impact on DA. For example, restoration of expression of
an inactive allele [32] coincides with the loss of trimethylated lysine in histones [33, 34]. It is conceivable
that multiple histone modifications may need to be targeted to trigger an effect on DNA accessibility at higher
levels of chromatin organization [20]. Currently, there is
little evidence that these modifications are relevant to
metaphase chromatin accessibility, have a sustained effect on the higher order chromatin folding, or are even
present on mitotic chromosomes [35].
The majority of cells with DA show quantifiable nonrandom differences in accessibility between homologous
regions, typically expressed as a fraction of cells in a given
individual [13]. The near absence of marks of open interphase chromatin, moreover, from DA regions [13] may
confer differences in the chromatin state at the end of
interphase that affect the density, binding, or activity of
topoisomerase IIα to each allele. Our current results imply
that inhibition of topoisomerase IIα reverses DA and restores equivalent accessibility by preventing disparities in
superhelicity between homologous regions (Fig. 6). Otherwise, lax structural regulation by topoisomerase IIα in DA
regions would enable these differences to persist. One possible mechanism to explain this might be that the regions

where DA is observed in a fraction of cells are not as highly
structurally regulated as loci displaying equivalent accessibility to both homologs. Conversely, this hypothesis suggests that the structural state of equivalently accessible
regions maintains a strict degree of regulation, dictated in
part by an array of open chromatin marks established during the prior interphase, as previously demonstrated [13].
Given the above considerations on formation of DA or
equivalent accessible loci through separate topological
constraints on chromatin, it still remains to be determined what benefit, if any, such differences would have
in the cell. Our view is that DA is a structural feature
that distinguishes homologous regions. Highly supercoiled regions with decreased accessibility alternate with
more accessible domains along a chromosome. Decondensation at the end of mitosis could be driven by unwinding in these regions.
In interphase, homologous chromosomes are in repulsion relative to heterologous pairs [36]. Regions with DA
may also spatially organize homologous regions in the
mitotic nucleus. Such a mechanism could prevent allelic
regions from being co-localized [36, 37] at or near DA
loci, whereas equivalently accessible loci could be
spatially clustered in the nucleus [38, 39].
Chromatin and transcriptional patterns of genes detected by single copy probes do not support a role for
DA in regulation of expression. mRNA levels of these
genes are very low or undetectable (Additional file 8:
Table S2). Autosomal monoallelic expression [37] is
therefore unlikely to be an effect of DA. Further, histone
marks of transcriptionally active chromatin (H3K36me3,
H4K20me1) do not significantly differ between DA and
equivalently accessible loci (Additional file 8: Table S2).
Finally, topoisomerase inhibitors have inconsistent effects on gene expression in DA regions. Topoisomerase
poisons, such as camptothecin, which primarily inhibit
topoisomerase I activity but also partially effect topoisomerase II, have been shown to downregulate RGS7
(1.8 fold reduction), SNRPN (3.1 fold reduction), HERC2
(2.2 fold reduction), PMP22:IVS4-Ex5 (1.6 fold reduction), PMP22:IVS3 (1.6 fold reduction), and ACR (1.38
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Fig. 6 Working model of solenoidal supercoiling between homologous regions with differential accessibility. The model illustrates localized
differences in chromatin accessibility at specific homologous loci in untreated cells (i.e. with DA, default state). Example of a homologous
chromosomal region within 17p12 (black rectangle) ideogram is shown in the middle of the illustration. Immediately flanking each ideogram,
chromatin loop size, its frequency, and distance between each helical turn (i.e. helical pitch) is kept the same for both homologs but
inter-homolog accessibility within a localized loop is depicted to be variable. For homologous region A, this is illustrated as low-level compaction
with widely spaced gray circles in contrast with high-level compaction in homologous region B. The outer most images show a partial cross
section of each loop. In homolog A, the solenoid structure with greater accessibility has low longitudinal supercoiling vs. homolog B. For
simplicity, additional levels of packing beyond the 300 nm loop fiber (indicated by multiple black arrows) are not shown. Chromatin loops are
drawn in two-dimensions of a 3-D configuration found in vivo

fold reduction), but upregulate CACNA1B and ADORA2B
by 1.21 and 1.44 fold, respectively [40]. Given these findings, it is possible that the observed differences in mitotic
chromatin accessibility are not sufficient to dictate
changes in gene expression.
DA is the result of differential activity by topoisomerase
IIα at specific loci and particular homologous chromosomes. From chromosome conformation capture data
[35], others have suggested that the formation of DA or
equivalent accessible loci occurs de novo in every cell. This
seems unlikely in light of the results reported here and in
our previous study demonstrating that DA was transmitted from parental to progeny cells, and between related individuals [13].

Conclusions
In conclusion, we show that DA is a stable structural
mark of metaphase chromosomes that was not influenced by inhibitors of histone-modification, cytosine
methylation or cohesin mutations that alter chromosome accessibility during interphase. Nevertheless, inhibition of topoisomerase IIα can reverse DA. We
demonstrate that targeting the catalytic activity of ATPbound DNA topoisomerase IIα, equalizes superhelical
densities between metaphase chromosome homologs in
locus-specific regions of DA. This raises the possibility
that in normal untreated cells, the winding number of

topoisomerase-induced, solenoidal supercoils can vary
between homologous sequences within these regions
(Fig. 6). Combined with our previous study [13], this
suggests that DA is the result of variable catenation
levels at specific loci which are distinguishable and heritable between homologous chromosomes.

Methods
Cell line and single copy DNA probe selection

Human lymphoblastoid cell lines were obtained from
NIGMS Human Genetic Cell Repository [Coriell Institute,
Camden, New Jersey]. These cell lines were selected based
on microscopically visible chromosome translocations of
known parental origins in which DA probes were hybridized. The translocations were used to mark cytogenetically
distinguishable parental homologs in order to determine
whether or not DA occurred randomly between homologs. This approach obviated the need to use other
methods such as parental origin determination (PODFISH) [41] to discriminate homologs. The characterization
of DA on cell lines used in the present study (GM06326,
GM10958) has been previously determined by single copy
DNA FISH probes [13]. The homologous targets detected
by these FISH probes are chromosomally normal. Additional cell lines with mutations of core cohesin components (Coriell Institute; GM20000, GM20466; Additional
file 1: Table S1), causing chromatin decompaction [21],
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were also tested as potential indicators for DA. Single copy
FISH probes detecting no DA (i.e. equivalent accessibility)
(C9orf66, PMP22:IVS–Ex4) [13] were used as control hybridizations in cells with cohesin mutations alongside DA
probes (CACNA1B, PMP22:IVS3). All cells were cultured,
harvested for metaphase chromosomes, and processed for
single copy FISH as described previously [42, 43].
Lymphoblastoid cells were cultured in RPMI-1640
medium (Gibco, Life Technologies Inc. ON, Canada) supplemented with L-glutamine, 15 % fetal bovine serum
(Gibco) and 1 % penicillin/streptomycin (Gibco). Chromosomes were harvested in logarithmic growth by arresting
cells in metaphase [10 μg/ml colcemid, Gibco) followed
by incubating in 0.075 M KCl hypotonic solution and subsequently fixing the cells in 3:1 methanol:acetic solution.
Single copy probes detecting DA were tested on different
concentrations of decondensation treatments in each cell
line (Additional file 1: Table S1). Probes were selected
from within chromosomal regions representative of telomeric, pericentromeric and loci adjacent to these sites.
Details by which single copy probes are designed, developed and used to analyse differences in chromatin accessibility has been described elsewhere [11–13, 31].
Genomic locations of single copy intervals were determined computationally [31], and they can be developed
from any unique region in the genome (e.g. exons, introns,
intergenic). Unlike BAC, cosmid or fosmid probes, single
copy probes do not contain high copy repetitive elements.
They were amplified using long PCR from genomic DNA
and labelled by nick translation with biotin-dUTP (Roche
Diagnostics, ON, Canada) or digoxigenin-dUTP (Roche
Diagnostics, ON, Canada). Labelled single copy probes
were detected with Cy™3 conjugated to IgG fraction monoclonal mouse anti-digoxin (Jackson ImmunoResearch, PA,
USA) (diluted 1:200 [1.7 mg/ml]) or Alexa Fluor® 488 conjugated to streptavidin (Jackson ImmunoResearch, PA,
USA) (diluted 1:500 [1.5 mg/ml]) [11–13] .
Chromatin decondensation treatments

Chromatin-modifying reagents were incorporated in vitro
into rapidly dividing, nonsynchronized lymphoblastoid cell
cultures. The reagents targeting non-histone proteins included ICRF-193 (a bisdioxopiperazine derivative inhibitor
of mammalian DNA topoisomerase IIα; Sigma-Aldrich)
and 5-AZC (inhibits DNA methyltransferase; SigmaAldrich). Condensin mutations were not studied because
they result in a loss of chromosome structural integrity and
mislocalization of topoisomerase IIα [44]. Targets of histone
proteins included OA (inhibitor of protein phosphatase I
and IIα; Sigma-Aldrich), TSA (inhibitor of histone deacetylase; Sigma-Aldrich), and UNC1999 (small molecule inhibitor of histone lysine methyltransferases EZH2 and EZH1
catalyzing H3K27me3; Sigma-Aldrich). Each treatment
dose (Additional file 1: Table S1) was optimized to our
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experimental design using baseline concentrations previously reported from pharmacokinetic, biochemical, and
cytological studies on lymphocyte, HeLa or MCF-7 cells
[5–9]. This was important, as it minimized cell toxicity and
preserved chromosome morphology and banding for
homolog identification following FISH. Specifically, final
concentrations in cell culture ranged from 0.05–3 μM
(ICRF-193), 0.1–0.5 μM (OA), 0.2–15 μM (TSA), 5–45 μM
(UNC1999), and 3.5–35 μM (5-AZC). Using published time
points as a baseline [5–9], duration in cell culture was 0.5,
1, 20, 72, and 7 h for ICRF-193, OA, TSA, UNC1999 and
5-AZC, respectively. Changes to higher order chromatin
structure were visualized by DAPI-staining and epifluorescence microscopy before performing metaphase FISH. Untreated control cell cultures (i.e. no decondensation
treatments) were taken through the chromosome harvest
and FISH procedures simultaneously with treated cells.
For ICRF-193 treated and untreated cultures, 50 metaphases from each concentration (0, 0.1 μM, 0.25 μM,
0.50 μM) were assessed for chromosome resolution according to ISCN 2013 [14]. Dark bands were counted on
at least two of chromosome regions 6p, 17q, 18q, 15q12/
q24qter, or 22q in the cell lines. These chromosomal regions were selected because they are informative at most
ISCN band resolution levels [14] and could be readily
identified amongst the entangled, catenated chromosomes. Differences in chromosome resolution with varying ICRF-193 treatments were analyzed for significance
(α = 0.05, one-way ANOVA test).
Immunofluorescence

Immunofluorescence staining of nuclear histone protein
H3K27me3 was achieved with a rabbit IgG monoclonal
antibody to H3K27me3 according to the manufacturer’s
protocol (Cell Signaling Technologies). This was performed to determine whether UNC1999 had an effect in
reducing H3K27me3. Briefly, human lymphoblastoid
cells were fixed in methanol/water (50:50 vol/vol), immediately spun onto microscope slides using a cytospin
microcytocentrifuge (Statspin®), immersed in blocking
buffer (0.3 % triton X-100 with 3 % BSA in 1X PBS) for
1 h, and incubated with a primary rabbit monoclonal
antibody against H3K27me3 overnight at 4 °C (antibody
diluted in same diluent as blocking buffer except with
1 % BSA). Cells were washed in 1X PBS and detected
with goat anti-rabbit IgG conjugated to Dylight® 488
fluorochrome (Abcam®) for 1 h at 37 °C, followed by
three 5 min washes in 1X PBS, and counterstained with
DAPI. Nuclei were examined for presence of punctuate
granular fluorescent signals. All UNC1999-treated cell
cultures were set-up in duplicate. One set was harvested
for metaphase chromosomes to evaluate the level of DA
and the corresponding culture set was processed for immunofluorescence staining of nuclei, as described above.
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Quantification of DA following metaphase chromosome
decondensation

Single copy FISH probe hybridization analysis was performed on Zeiss AxioImager.Z2 epifluorescence microscope and cells imaged with a CoolCube 1 camera using
Metafer software (Metasystems). With background corrected, integrated probe signal intensities were determined
using our previously described gradient vector flow (GVF)
algorithm [13, 16]. GVF outlines the boundary of scFISH
probe signals by computing a binary edge map from the
gray scale image. From this active contour, the integrated
intensity values (in pixels) were automatically computed for
probe signal on each homolog in MATLAB, and a GVF result of the binary contour provided as an output. Probe signal intensities were then normalized by taking the difference
in integrated intensities between homologs, and dividing by
the sum of the intensities of both homologs in a given cell.
Using 3D-SIM (Nikon Corporation), inter-homolog
probe volume and depth were also quantified in treated
cells relative to untreated controls. 3D-SIM images were reconstructed with NIS-Elements AR software (version
4.13.00, Nikon Canada Inc.) as previously described [13].
The lateral fluorescence depth of a probe’s signal on a given
homolog was calculated from reconstructed optical sections. Reconstructed optical sections were generated by taking the 2D layers of a captured image (each layer
corresponding to an optical slice) and superimposing each
layer into a 3D projection using Z-stack ND module within
NIS-Elements. Each section was collected in 0.13 μm steps
from a total of 17 reconstructed optical sections. The reconstructed image of the metaphase chromosome was then
displayed in 3D volume view. The Nikon Elements Movie
Maker option in ‘Directors Mode’ was subsequently used to
add key frames in order to define the initial zoom, position,
and rotation of the 3D metaphase chromosome in object
space. The final movie was created by interpolation between these key frames. Predefined rotation presets
were implemented which combined a 360° turn around
the X/Y/Z-axis, while building up the image with additional
sections along the Z plane. Volume of probe fluorescence
was calculated following image segmentation and thresholding. All parameters quantified were analyzed for significance (α = 0.05, two-tailed t test).
Internal hybridization controls

BAC probes (obtained from The Center for Applied
Genomics, Toronto), were co-hybridized with scFISH
probes, as positive hybridization controls and to identify
the homologs of interest in ICRF-193 treated samples.
BAC probes were labelled with Spectrum Green-dUTP
(Abbott Molecular) and were located on chromosome
9p21.2 and 11q12.2, spanning 187 kb (RP11-57P14) and
188 kb (RP11-467L20), respectively. DA was not observed using BAC probes. For example, the mean
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normalized probe fluorescence intensity differences between homologs for a BAC probe mapping to chromosome
9p21.2 (RP11-57P14), that was co-hybridized with the
scFISH probe from CACNA1B, was Δμ = 0.147 [0.25 μM
ICRF-193] and Δμ = 0.156 [0.10 μM ICRF-193] (Additional
file 9: Figure S5A-B, Additional file 10: Table S3). Similarly
BAC probe RP11-467L20, that was co-hybridized with the
scFISH probe from RGS7, exhibited mean normalized
probe fluorescence intensity differences of Δμ = 0.104
[at 0.50 μM ICRF-193] and Δμ = 0.162 [at 0.25 μM]
(Additional file 9: Figure S5C-D, Additional file 10:
Table S3). Inter-homolog chromatin compaction differences detected with scFISH probes showing DA, were not
evident with cohybridized BAC probes (Additional file 9:
Figure S5).

Evaluating Copy Number Variations (CNVs) in regions
with DA

Genomic locations of single copy probes were evaluated
relative to locations of common CNVs detected in two
normal control populations whose samples have been
tested with high resolution Affymetrix Cytoscan HD
copy number and SNP microarray platform. CNV datasets were derived from the Ontario Population Genomics (OPGP) Platform (~895 individuals of European
ancestry, at least 25 probes per CNV [45]) and Healthy
sample group (HS; ~400 individuals, at least 35 probes
per CNV; obtained from Affymetrix). Single copy probes
utilized in this study did not overlap any normal population CNVs (Additional file 8: Table S2). CNVs, therefore,
do not account for differences in probe hybridization intensities between homologous chromosomes [13].
Additionally, none of the single copy probe targets reported in the current study were localized close to the
CNVs in GM06326 (Additional file 8: Table S2). CNVs
in cell line GM06326, initially characterized using Affymetrix Genome-Wide Human SNP Array 6.0 [46], were
analysed in our laboratory using the Affymetrix
Chromosome Analysis Suite (ChAS). The intensity data
file (.CEL) from this cell line was converted into genotyping data files using the Affymetrix Genotyping
Console Software. The resulting copy number CHP
data file (.CNCHP) was visualized using Affymetrix
NetAffx (v. 32.1) library files with Affymetrix ChAS
software (high resolution setting: 100 kb gain or loss, at
least 50 probes per CNV). In GM06326, CNVs (>100 kb;
[GRCh37]) were observed on 7 chromosomes. They include:
1q43 (243,078,262 - 243,303,154; gain), 2p11.2 (89,144,03489,399,953; gain), 8p23.2 (3,899,581-4,283,153; gain),
8p11.22 (39,256,048-39,386,953; loss), 15q11.2 (21,104,6
04-22,317,726; loss), 16p11.2 (32,113,669-32,630,542, loss;
34,527,248-34,765,204, gain), 19p12 (21,256,875-21,393,137;
gain), and Xq21.31 (90,765,370-90,998,761; gain).
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Additional files
Additional file 1: Table S1. Human lymphoblastoid cell lines harvested
for metaphase chromosomes were hybridized with single copy (sc)
probes from indicated GRCh37 genomic coordinates. Concentrations of
each treatment, optimized for in situ hybridization are indicated. Only
cells treated with 5 μM of UNC1999 from GM10958 cell line were
included in the statistical analysis of DA for SNRPN and ADORA2B, due to
an insufficient number of mitoses at 15 μM. The numbers of metaphase
cells with and without (w/o) DA are indicated for each treatment dose
along with corresponding no treatment control prepared at the same
time.
Additional file 2: Figure S1. White box indicates zoom in view of
entangled or catenated metaphase chromosomes following (A)
0.25 μM and (B-C) 0.50 μM ICRF-193 treatment. Reduced supercoiling is
visible as cytologically unwound chromatids (*). Panel B is same cell as
shown in Fig. 1d.
Additional file 3: Figure S2. Immunofluorescence staining of
lymphoblastoid nuclei following selective inhibition of H3K27me3
associated with inactive chromatin. (A) H3K27me3 staining shows bright
punctate nuclear signals in untreated cells, but diminished fluorescence
and reduced signals post-treatment with (B) 5 μM and (C) 15 μM
UNC1999, respectively.
Additional file 4: Figure S3. Quantification of inter-homolog probe
fluorescence intensities following chromosome decondensation with
ICRF-193 in independent cell lines. (A–F) Box plots show normalized
integrated intensity ratios (y axis) following scFISH for six distinct genomic
regions within chromosomes 1q43 (RGS7), 9q34.3 (CACNA1B), 15q13.1
(HERC2), 17p12 (ADORA2B, PMP22:IVS3), and 22q13.33 (ACR) in untreated
(−) and treated (+) cells (x axis). GVF measurements in cells hybridized
with single copy probes detecting DA from within RGS7, HERC2,
PMP22:IVS3, and ACR are indicated from cell line GM10958. Measurements
of normalized inter-homolog intensities for CACNA1B and ADORA2B are
indicated from cell line GM06326. The same genomic regions were
hybridized in opposite cell lines and inter-homolog differences quantified
as shown in Fig. 3. Probes detecting DA exhibited larger differences in
inter-homolog DNA probe fluorescence (red box plots: median intensity
ratios: from 0.68 to 1, n = 125 cells). ICRF-193 treated chromosomes
exhibited smaller differences in DNA probe fluorescence (black box plots:
median intensity ratios from 0.15-0.39, n = 118 cells) (p < 0.05; two tail
t-test), suggesting retrieval of the less accessible chromosome target,
except in the case of HERC2, in which DA was not completely reversed.
In instances where the median is coincident with the upper quartile, it is
emphasized by a thick line to show distinction from the median in the
corresponding category.
Additional file 5: Movie S1. 3D anaglyph view of single copy FISH
target (PMP22:IVS3) between chromosome homologs. Chromosome 17
homologs appear in object space rotated 360° around the z axis at 15
frames per second to emphasize DNA probe volume in context of
reconstructed chromosomes. The parental homologs were
distinguishable based on a Y;17 chromosome translocation in cell line
GM06326, resulting in a normal chromosome 17 and a derivative (der)
17. Probe volume inside the metaphase chromosome in left panel
(corresponding to normal chromosome 17 in Fig. 4a) exhibits greater
occupancy compared to its less accessible target (right panel,
corresponding to der 17 in Fig. 4a), depicting inter-homolog DA from all
perspectives. Reconstructed optical sections were taken over 17 z-stacks,
at 0.13 μm per stack, with 3D-Structured Illumination Microscopy.
Additional file 6: Movie S2. 3D anaglyph view of single copy FISH
target (PMP22:IVS3) between chromosome homologs following
topoisomerase IIα inhibition. Chromosome 17 homologs appear in object
space rotated 360° around the z axis at 15 frames per second to emphasize
DNA probe volume in context of reconstructed chromosomes. Probe
volume inside the metaphase chromosome in left panel (corresponds to
normal chromosome 17 in Fig. 4b) is similar compared to the other
homologous target (right panel, corresponds to der 17 in Fig. 4b) depicting
equalization of DA from all angles. Bottom panels show still image of
equalized probe fluorescence without chromosome context. Reconstructed
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optical sections were taken over 17 z-stacks, at 0.13 μm per stack, with
3D-Structured Illumination Microscopy.
Additional file 7: Figure S4. Examples of DA in tetraploid-like cells after
okadaic acid treatment. (A) Chromosome 17s are marked with centromeric
probe (D17Z1, green) to identify the four copies in the tetraploid-like cell
(boxed). (B) Tetraploid-like cell shows two of the four homologs hybridized
with a 1.78 kb scFISH probe (red) within ADORA2B on chromosome 17p12,
indicating DA. (C) Zoom in view of the same cell from panel B shows a
bright hybridization to the normal chromosome 17 and a weaker
hybridization to its corresponding homolog (observed in n = 16/25 cells).
(D) The other pairs of normal chromosome 17 and der 17 (asterisk) showed
absence of hybridization to their respective allelic targets (n = 12/28 cells).
The same outcome shown in panel D was predominantly observed in a
region with no DA (PMP22: IVS-Ex5) in which two of the four homolog pairs
did not hybridize (n = 13/17 cells). Tetraploid-like cells with only single
chromosome hybridizations, hybridizations to only two normal
chromosome 17s or two der 17s were excluded, as they could not be
analyzed for DA which is assessed between homologs.
Additional file 8: Table S2. CNV and gene expression data in context of
regions with DA and equivalent accessibility. Single copy probe locations of
regions with DA (in bold) and equivalent accessibility (i.e. without DA) are
from indicated GRCh37 genomic coordinates. Overlapping CNVs in the
population from Healthy Sample (HS) and Ontario Population Genomics
Platform (OPGP) are separated by a “//.” No recurrent CNVs (diploid copy
number state) were observed in regions overlapped by single copy probes,
and are indicated by a “0”. A 179 kb gain in region of single copy probe
within C9orf66 was seen in only 1 out of ~400 HS individuals. This
observation is a rare CNV and the region in which it resides, does not
exhibit DA. SC probe locations do not overlap locations of CNVs reported in
cell line GM06326 (see methods). GM10958 cell line CNV data have not
been analyzed by genomic microarray analysis. This cell line has been
characterized as phenotypically normal (Coriell Cell Repository). Compared
to other tissues, mRNA abundance among human lymphocytes cells (EBV
transformed, n = 54 individuals) showed low or no expression (most values
below 0 on log10 scale, Genotype-Tissue Expression – GTEx database) for
each of the single copy probes tested. C9orf66 expression was not
catalogued in GTEx. The EMBL expression atlas (Illumina body map,
http://www.ebi.ac.uk/gxa/experiments/E-MTAB-513) confirmed that it is not
expressed in leukocytes. Marks of transcriptionally active chromatin
(i.e. H3K36me3, H4K20me1 - reported values represent integrated intensities)
were not significantly present (p = 0.91) in either DA (in bold, μ = 170.86) or
equivalent accessible genomic regions (μ = 161.15). Integrated intensity
values were processed from ENCODE ChIP-seq data on lymphoblastoid cell
line GM12878 using the Broad histone signal intensity ‘StdSig’ setting within
the UCSC Genome Table browser.
Additional file 9: Figure S5. Metaphase images of BAC FISH probes
co-hybridized with scFISH probes. (A) BAC probe (RP11-57P14; green),
which spans 187 kb on chromosome 9p21.2, consistently exhibits bright,
equivalent hybridization signals on both homologs. Co-hybridized scFISH
probe (red) is from within CACNA1B 9q34.3 treated with 0.25 μM (DA
reversed). (B) Same BAC and scFISH probe as in panel A co-hybridized to
metaphase chromosomes treated with 0.1 μM ICRF-193 (DA; asterisk
indicates inaccessible homolog). (C) BAC probe (RP11-467L20; green)
spanning 188 kb on chromosome 11q12.2 with bight signals to both
homologs (derivative or ‘der’ 11 is a result of a translocation between
chromosomes 1 and 11). Co-hybridized scFISH probe (red) is from within
RGS7 on 1q43 treated with 0.50 μM ICRF-193 (DA reversed). (D) Same
BAC and scFISH probe as in panel C co-hybridized to metaphase
chromosomes treated with 0.25 μM ICRF-193 (DA; asterisk indicates
inaccessible homolog without RGS7 hybridization).
Additional file 10: Table S3. GVF measurements of BAC control FISH
probe signal co-hybridized with scFISH probes. Columns labelled A and B
represent integrated intensity measurements for each homolog in a
diploid metaphase cell. Normalized integrated intensities were obtained
by taking the difference in integrated intensities between homologs, and
dividing by the sum of the intensities of both homologs in a given cell.
Slides 1 (0.25 μM ICRF-193) and 2 (0.10 μM ICRF-193) were processed in
parallel and co-hybridized with BAC control probe RP11-57P14 and
scFISH probe CACNA1B with DA. Irrespective of whether ICRF-193
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reversed DA (slide 1, 0.25 uM ICRF) or showed limited effect (slide 2),
control probes hybridized with consistently bright intensities to both
homologs. No significant differences (p = 0.85) were observed in
normalized integrated intensities among control probes between slides 1
(Δμ = 0.147, Median = 0.156) and 2 (Δμ = 0.156, Median = 0.123). Slides 3
(0.50 uM ICRF) and 4 (0.25 uM ICRF) were processed in separate
hybridizations and co-hybridized with BAC control probe RP11-467L20
and scFISH probe RGS7 with DA. Similarly, no significant differences
(p = 0.12) were observed in normalized integrated intensities among
control probes between slides 3 (Δμ = 0.104, Median = 0.078) and 4
(Δμ = 0.162, Median = 0.110).
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